Dyne cut to Perform at Oppenheimer on valuation

[Wall Street New York stock exchange stock market]
alexsl

Shares of Dyne Therapeutics (NASDAQ:DYN [https://seekingalpha.com/symbol/DYN]) fell on Friday after Oppenheimer downgraded the neuromuscular disease company to Perform from Outperform, citing concerns over its valuation ahead of key data readouts expected this year.

Analyst Andreas Argyrides pointed to data the company presented this week at a medical event for its nucleotide-based therapy DYNE-101 in myotonic dystrophy type 1, a rare neuromuscular disease. [https://seekingalpha.com/news/4502392-dyne-therapeutics-rises-on-positive-data-from-myotonic-dystrophy-trial]

While data from the Phase 1/2 trial highlighted DYNE-101's effect on functional outcomes, strength, patient-reported outcomes, and overall disease burden, validating it as a potential DM1 therapy, the analyst cited concerns over the strength of data.

“We view powering of the pivotal study (mid-2026 readout) as a key overhang given the small cohort size and statistical variability,” Argyrides wrote, maintaining his $13 target on the company for the next 12–18 months.

With Dyne (NASDAQ:DYN [https://seekingalpha.com/symbol/DYN]) joining the biotech sector’s rally over the past month, the analyst moves to the sidelines, citing concerns over the stock’s valuation and a pivotal readout expected from its Duchenne candidate DYNE-251 later this year. [https://seekingalpha.com/news/4477210-dyne-gets-fda-breakthrough-therapy-status-for-dmd-therapy]

MORE ON DYNE THERAPEUTICS

* Dyne: Accelerated Approval Established Endpoint Sets Stage For DM1 Data In Mid-2026 [https://seekingalpha.com/article/4828650-dyne-accelerated-approval-established-endpoint-sets-stage-for-dm1-data]
* Dyne Therapeutics' Valuation Leaves No Room For Error [https://seekingalpha.com/article/4827651-dyne-therapeutics-valuation-leaves-no-room-for-error]
* Dyne Therapeutics, Inc. (DYN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) [https://seekingalpha.com/article/4820499-dyne-therapeutics-inc-dyn-presents-at-morgan-stanley-23rd-annual-global-healthcare-conference]
* Dyne Therapeutics rises on positive data from myotonic dystrophy trial [https://seekingalpha.com/news/4502392-dyne-therapeutics-rises-on-positive-data-from-myotonic-dystrophy-trial]
* Avidity Biosciences jumps on report of Novartis takeover approach [https://seekingalpha.com/news/4480029-avidity-biosciences-jumps-on-report-of-novartis-takeover-approach]